ALTS vs. CRVO, ELUT, MNOV, ANIX, ELDN, MGX, IVVD, ALXO, CRDF, and GNLX
Should you be buying Janone stock or one of its competitors? The main competitors of Janone include CervoMed (CRVO), Elutia (ELUT), MediciNova (MNOV), Anixa Biosciences (ANIX), Eledon Pharmaceuticals (ELDN), Metagenomi (MGX), Invivyd (IVVD), ALX Oncology (ALXO), Cardiff Oncology (CRDF), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.
CervoMed (NASDAQ:CRVO) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
CervoMed has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Janone has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500.
CervoMed has higher revenue and earnings than Janone.
25.2% of CervoMed shares are owned by institutional investors. 2.0% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, CervoMed had 1 more articles in the media than Janone. MarketBeat recorded 1 mentions for CervoMed and 0 mentions for Janone. CervoMed's average media sentiment score of 1.94 beat Janone's score of 0.00 indicating that CervoMed is being referred to more favorably in the media.
CervoMed received 6 more outperform votes than Janone when rated by MarketBeat users.
CervoMed presently has a consensus target price of $53.25, indicating a potential upside of 271.08%. Given CervoMed's higher probable upside, equities research analysts clearly believe CervoMed is more favorable than Janone.
Janone has a net margin of 0.00% compared to CervoMed's net margin of -52.24%. CervoMed's return on equity of -27.91% beat Janone's return on equity.
Summary
CervoMed beats Janone on 12 of the 14 factors compared between the two stocks.
Get Janone News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free ALTS Stock Alerts